• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Iron Deficiency Anemia - Pipeline Review, H1 2012 Product Image

Iron Deficiency Anemia - Pipeline Review, H1 2012

  • Published: April 2012
  • 46 pages
  • Global Markets Direct

Iron Deficiency Anemia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Iron Deficiency Anemia - Pipeline Review, H1 2012', provides an overview of the Iron Deficiency Anemia therapeutic pipeline. This report provides information on the therapeutic development for Iron Deficiency Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia. 'Iron Deficiency Anemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Iron Deficiency Anemia.
- A review of the Iron Deficiency Anemia products under development by READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia Overview
Therapeutics Development
An Overview of Pipeline Products for Iron Deficiency Anemia
Iron Deficiency Anemia Therapeutics under Development by Companies
Iron Deficiency Anemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Iron Deficiency Anemia Therapeutics – Products under Development by Companies
Iron Deficiency Anemia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Iron Deficiency Anemia Therapeutics Development
AMAG Pharmaceuticals, Inc.
Rockwell Medical Technologies, Inc.
Galenica Ltd.
Iron Deficiency Anemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SFP-Peritoneal Dialysis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SFP-Oral Prescription - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Feraheme - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SFP-Hemodialysis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Injectafer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proferrin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ST10-021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iron Deficiency Anemia Therapeutics – Drug Profile Updates
Iron Deficiency Anemia Therapeutics - Dormant Products
Iron Deficiency Anemia – Product Development Milestones
Featured News & Press Releases
Mar 07, 2012: AMAG Pharmaceuticals Announces Preliminary Results From Phase III Study Evaluating Feraheme Compared To IV Iron Sucrose In Patients With Iron Deficiency Anemia
Jan 30, 2012: AMAG Pharmaceuticals Completes Enrollment In Phase III Program Evaluating Feraheme For Broader Iron Deficiency Anemia Indication
Dec 15, 2011: FDA Assigns PDUFA Date For Injectafer NDA
Dec 12, 2011: AMAG Pharmaceuticals Announces Preliminary Data Regarding Safety and Efficacy Of Single Infusion Of 1020mg Ferumoxytol in Patients With Iron Deficiency Anemia
Dec 12, 2011: AMAG Receives Approval From Health Canada For Feraheme For Treatment Of Iron Deficiency Anemia in Adults with Chronic Kidney Disease
Nov 12, 2011: AMAG Pharmaceuticals Announces Positive Data From FIRST Head-to-Head Trial Comparing Ferumoxytol To Iron Sucrose
Nov 11, 2011: Galenica Announces Presentation Of New Injectafer Data At American Society Of Nephrology’s Kidney Week 2011
Nov 02, 2011: AMAG Pharmaceuticals To Present New Data On Feraheme At American Society of Nephrology Kidney Week 2011
Oct 13, 2011: Luitpold Submits NDA With FDA For Injectafer In Iron Deficiency Anemia
Oct 12, 2011: Shield Therapeutics Initiates AEGIS 1 And AEGIS 2 Phase III Studies Of ST10
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Iron Deficiency Anemia, H1 2012
Products under Development for Iron Deficiency Anemia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
AMAG Pharmaceuticals, Inc., H1 2012
Rockwell Medical Technologies, Inc., H1 2012
Galenica Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Iron Deficiency Anemia Therapeutics – Drug Profile Updates
Iron Deficiency Anemia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Iron Deficiency Anemia, H1 2012
Products under Development for Iron Deficiency Anemia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos